Healthcare / BiotechnologyNasdaqCM
$0.92
+0.01 (+1.32%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-10.3M · quality 70.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$42M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-206.0%
↓Gross Margin
70.9%
↑Debt/Equity
0.04
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-977.3%
FCF / Net income
0.98x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.1M · net income $-11.2M · FCF $-11.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $1.1M | $1.1M | $43000.00 | — | — | — | — |
| Net Income | $-11.2M | $-11.2M | $-8.8M | $-10.2M | $-9.9M | $-6.3M | $-3.8M |
| EBITDA | $-12.5M | $-12.5M | $-11.0M | $-11.4M | $-9.9M | — | — |
| EPS | — | — | -0.40 | -0.99 | -1.09 | -1.21 | — |
| Gross Margin | 70.9% | 70.9% | 100.0% | — | — | — | — |
| Operating Margin | -1114.1% | -1114.1% | -25511.6% | — | — | — | — |
| Net Margin | -994.5% | -994.5% | -20497.7% | — | — | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.04 | 0.04 | 0.06 | — | — | — | — |
| Current Ratio | 7.15 | 7.15 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-11.0M | $-11.0M | $-9.1M | $-10.3M | $-8.8M | — | — |
| Returns | |||||||
| ROE | -206.0% | -206.0% | -196.8% | 341.1% | -160.5% | -41.2% | 25.9% |
| Valuation | |||||||
| P/B | 6.22 | 6.22 | 6.86 | — | 4.44 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 2511.6% | 2511.6% | — | — | — | — | — |
| EPS Growth | — | — | 59.6% | 9.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-34.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.40 → n/d
Residual
-34.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.